AdAlta : PAC Partners Healthcare Conference - Corporate Presentation

5 April 2022

For personal use only

ASX Announcement

ADALTA TO PRESENT AT INAUGURAL PAC PARTNERS HEALTHCARE CONFERENCE

MELBOURNE Australia, 5 April 2022: AdAlta Limited (ASX:1AD) the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to be presenting at the Inaugural PAC Partners Healthcare Conference, to be held in Sydney on 6 April 2022.

Dr Tim Oldham, CEO and Managing Director, will deliver a presentation entitled "Developing high value drugs for challenging diseases" that will showcase four human health needs that AdAlta's i-body platform and product pipeline is addressing today:

• • Traditional antibodies cannot address all diseases - AdAlta's i-bodies are a differentiated drug discovery platform for difficult diseases;

• • Idiopathic pulmonary fibrosis is a degenerative and fatal disease with no good treatment today - AdAlta's lead product AD-214 could mee a desperate need to new approaches to this debilitating disease;

• • Immuno-oncology drugs are revolutionising cancer outcomes, however not all patients respond - AdAlta and GE Healthcare's granzyme B iPET imaging agent could help identify responders and non-responders early; and

• • CAR-T cell therapy is providing new hope for patients with blood cancers who have exhausted all other options - AdAlta and Carina Biotech's iCAR-T cell therapies aim to offer the same hope to patients with solid tumours.

The presentation will also set out experimental and other milestones for the remainder of 2022.

A copy of the presentation, together with an appendix containing previously announced supporting technical data is attached.

Authorised for lodgement by:

Tim Oldham

CEO and Managing Director April 2022

Notes to Editors About AdAlta

For personal use only

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at:https://adalta.com.au

For more information, please contact:

Investors	Media
Tim Oldham, CEO & Managing Director	IR Department
Tel: [phone]	Tel: [phone]
E:[e-mail]	E:[e-mail]

Disclaimer

onal use only

Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in AdAlta, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

INVESTOR PRESENTATION - APRIL 2022

This presentation may contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the company's research and development. Any statement describing a goal, expectation, intention or belief of the company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities.

There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

AdAlta at a glance

INVESTOR PRESENTATION - APRIL 2022

AdAlta's i-body platform is enabling a high-value product pipeline in two therapeutic areas of significant unmet medical need